Literature DB >> 26130832

Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014).

Caitlin C Rothacker1, Ashley G Boyle1, David G Levine1.   

Abstract

The purpose of this retrospective case series was to assess the outcome of an autologous vaccination procedure on single and multiple sarcoid lesions, determine complication rate, and report owner satisfaction. Medical records (18 cases) from January 2009 through May 2014 were evaluated to identify horses undergoing the procedure. Signalment, number, size, anatomic location of lesions, and type of historical treatment were recorded. Follow-up was obtained via standardized owner survey, veterinary examination, and digital images. Data recorded and analyzed included ancillary therapies post-procedure, decrease in number and/or size of sarcoid lesions, sarcoid regrowth, complications, and owner satisfaction. There was a decrease in number of lesions observed by owners in 75% of cases and a decrease in size of sarcoids in 93.8% of cases. Clinical regression observed by owners was noted in 68.8% of cases. There were complications in 43.8% of cases and owner satisfaction in 75% of cases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130832      PMCID: PMC4466821     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  25 in total

1.  Equine sarcoid tumour treated by autogenous tumour vaccine.

Authors:  R E Kinnunen; T Tallberg; H Stenbäck; S Sarna
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

2.  HIV suppression by interleukin-16.

Authors:  M Baier; A Werner; N Bannert; K Metzner; R Kurth
Journal:  Nature       Date:  1995-12-07       Impact factor: 49.962

Review 3.  Immunomodulation in horses.

Authors:  B R Rush; M J Flaminio
Journal:  Vet Clin North Am Equine Pract       Date:  2000-04       Impact factor: 1.792

Review 4.  A systematic review of the immune-modulators Parapoxvirus ovis and Propionibacterium acnes for the prevention of respiratory disease and other infections in the horse.

Authors:  R Paillot
Journal:  Vet Immunol Immunopathol       Date:  2013-02-05       Impact factor: 2.046

5.  BCG emulsion immunotherapy of equine sarcoid.

Authors:  B A Vanselow; I Abetz; A R Jackson
Journal:  Equine Vet J       Date:  1988-11       Impact factor: 2.888

6.  Iridium-192 interstitial brachytherapy for equine periocular tumours: treatment results and prognostic factors in 115 horses.

Authors:  A P Théon; J R Pascoe
Journal:  Equine Vet J       Date:  1995-03       Impact factor: 2.888

7.  Intratumoral chemotherapy with cisplatin in oily emulsion in horses.

Authors:  A P Théon; J R Pascoe; G P Carlson; D N Krag
Journal:  J Am Vet Med Assoc       Date:  1993-01-15       Impact factor: 1.936

8.  Equine leukocyte antigens: relationships with sarcoid tumors and laminitis in two pure breeds.

Authors:  D Meredith; A H Elser; B Wolf; L R Soma; W J Donawick; S Lazary
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

9.  HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

Authors:  Mariette I E van Poelgeest; Marij J P Welters; Edith M G van Esch; Linda F M Stynenbosch; Gijs Kerpershoek; Els L van Persijn van Meerten; Muriel van den Hende; Margriet J G Löwik; Dorien M A Berends-van der Meer; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Sjoerd H van der Burg
Journal:  J Transl Med       Date:  2013-04-04       Impact factor: 5.531

Review 10.  Immunologic treatments for precancerous lesions and uterine cervical cancer.

Authors:  Patrizia Vici; Luciano Mariani; Laura Pizzuti; Domenico Sergi; Luigi Di Lauro; Enrico Vizza; Federica Tomao; Silverio Tomao; Claudia Cavallotti; Francesca Paolini; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2014-03-26
View more
  3 in total

Review 1.  Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.

Authors:  Virgil Schijns; Alberto Fernández-Tejada; Žarko Barjaktarović; Ilias Bouzalas; Jens Brimnes; Sergey Chernysh; Sveinbjorn Gizurarson; Ihsan Gursel; Žiga Jakopin; Maria Lawrenz; Cristina Nativi; Stephane Paul; Gabriel Kristian Pedersen; Camillo Rosano; Ane Ruiz-de-Angulo; Bram Slütter; Aneesh Thakur; Dennis Christensen; Ed C Lavelle
Journal:  Immunol Rev       Date:  2020-06-28       Impact factor: 12.988

2.  Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Authors:  Christoph Jindra; Edmund K Hainisch; Andrea Rümmele; Markus Wolschek; Thomas Muster; Sabine Brandt
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

3.  ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.

Authors:  Corey Saba; Randall Eggleston; Andrew Parks; John Peroni; Eric Sjoberg; Shelbe Rice; Jesse Tyma; Jarred Williams; Deborah Grosenbaugh; A Timothy Leard
Journal:  J Vet Intern Med       Date:  2022-04-13       Impact factor: 3.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.